CompoAtlas

GRANDE CAMOMILLE

Food supplement declared in France, declaration No 2021-6-1463, decision dated 28 June 2021

GRANDE CAMOMILLE (NATUR!ST) is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition.

Brand
NATUR!ST
Food business operator placing the product on the market
ROZAE
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Powder
Daily dose
1,2G
Directions for use
2 petites cuillères doseuses rases par jour
Objectives stated by the manufacturer (these are not authorised claims)
Menstrual cycles, Menopause

Declaration 316836, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Tanacetum parthenium (L.) Sch.Bip.Parties aériennesPoudre (de plantes séchées ou broyées)1.2 g

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Déconseillé chez les personnes présentant une hypersensibilité aux Astéracées.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Tanacetum parthenium (L.) Sch.Bip.
    Read the warning, when it applies and the studies cited

    FEVERFEW - TANACETUM PARTHENIUM

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Biggs et al. 1982).

    Sources cited by Health Canada (2)
    • Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;320(8301):776. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are breastfeeding (Boon 2000).

    Sources cited by Health Canada (1)
    • Boon H. Feverfew. In: Chandler F, editor. Herbs: Everyday Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association and the Canadian Medical Association; 2000.

    Contraindications

    Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.

    Do not use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    Applies to products providing more than 250 mg of dried herb top and/or leaf, per day.

    Do not use if you are pregnant or breastfeeding (EMA 2020).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2020; Paulsen et al. 2001; Hausen 1996).

    Sources cited by Health Canada (2)
    • Hausen BM. A 6-year experience with compositae mix. American Journal of Contact Dermatitis 1996;7(2):94-99. PubMed
    • Paulsen E, Anderson KE and Hausen BM. Sensitization and cross-reaction patterns in Danish Compositae-allergic patients. Contact Dermatitis 2001;45(4):197-204. PubMed

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product you may experience sore mouth, mouth ulcers and/or gastrointestinal discomfort/disturbances (EMA 2020; Gardner and McGuffin 2013; Murphy et al. 1988; Johnson et al. 1985).

    Sources cited by Health Canada (3)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Johnson ES, Kadam NP, Hylands DM, Hylands PJ. 1985. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal 291(6495):569-573.
    • Murphy JJ, Heptinstall S, Mitchell JR. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;332(8604):189-192.

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

This name is used by more than 10 declarations from different companies, so it does not identify one product. See every declaration with this name.

Brand : NATUR!ST

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2021. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line